Author： Wauters Jan
Publisher： Palgrave Macmillan Ltd
ISSN： 1478-565X
Source： Journal of Commercial Biotechnology, Vol.16, Iss.2, 2010-04, pp. : 168-173
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
It has never been as challenging in biotechnology as today. Convergence is the key word, forcing alliances between pharmaceuticals and biology, and new economic opportunities arise from the growing interface between biotechnology and nanotechnology, nanobio. The challenges to bring such disruptive technologies to the market are unprecedented, ranging from truly multidisciplinary research to matching totally different business models among the various industries. In Flanders, Belgium, the message has been understood already 20 years ago.
Related content
Biotechnology education in Europe
By Moses Vivian
Journal of Commercial Biotechnology, Vol. 9, Iss. 3, 2003-03 ,pp. :
Access to resources
Recommend
Promoting the competitiveness of biotechnology in Europe
By Lex M.
Trends in Biotechnology, Vol. 13, Iss. 2, 1995-02 ,pp. :
Venture capital and the European biotechnology industry
Journal of Commercial Biotechnology, Vol. 15, Iss. 3, 2009-07 ,pp. :
The class of 2004: Human capital in biotechnology
Journal of Commercial Biotechnology, Vol. 10, Iss. 4, 2004-06 ,pp. :